RAS was called undruggable.
RAS was called undruggable. “For over two decades, RAS carried one of the most dispiriting labels in drug discovery: undruggable.” A new drug, daraxonrasib, roughly doubled survival in metastatic pancreatic cancer in Phase 3, and it is part of a broader wave of medicines that can target proteins without obvious binding pockets. ~ learn more